Ioannis Panagopoulos1, Ludmila Gorunova2, Henning Leske3, Pitt Niehusmann3, Lene E Johannessen2, Julie Staurseth2, Nina Øino2, Torstein R Meling4,5, Sverre Heim2,4, Francesca Micci2, Petter Brandal2,6. 1. Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway ioannis.panagopoulos@rr-research.no. 2. Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. 3. Department of Pathology, Oslo University Hospital, Oslo, Norway. 4. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. 5. Department of Neurosurgery, Rikshospitalet, Oslo University Hospital, Oslo, Norway. 6. Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Abstract
BACKGROUND: Methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter is a well-established predictor of response to the DNA-alkylating agent temozolomide in patients with glioblastoma. MATERIALS AND METHODS: Pyrosequencing analysis was used to determine the MGMT promoter methylation status in 61 meningiomas, to clarify whether it might have a predictive role. RESULTS: Only two tumors (3%) had a mean methylation frequency higher than the cut-off value of 10% for the four CpG sites examined. CONCLUSION: The methylation of the MGMT promoter is uncommon, or occurs at a low frequency in meningiomas. There is no convincing rationale to test such tumors for their MGMT methylation status in a clinical setting. Copyright
BACKGROUND: Methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter is a well-established predictor of response to the DNA-alkylating agent temozolomide in patients with glioblastoma. MATERIALS AND METHODS: Pyrosequencing analysis was used to determine the MGMT promoter methylation status in 61 meningiomas, to clarify whether it might have a predictive role. RESULTS: Only two tumors (3%) had a mean methylation frequency higher than the cut-off value of 10% for the four CpG sites examined. CONCLUSION: The methylation of the MGMT promoter is uncommon, or occurs at a low frequency in meningiomas. There is no convincing rationale to test such tumors for their MGMT methylation status in a clinical setting. Copyright
Authors: Milena Cankovic; Marina N Nikiforova; Matija Snuderl; Adekunle M Adesina; Neal Lindeman; Patrick Y Wen; Eudocia Q Lee Journal: J Mol Diagn Date: 2013-07-17 Impact factor: 5.568
Authors: M Josefa Bello; Cinthia Amiñoso; Isabel Lopez-Marin; Dolores Arjona; Pilar Gonzalez-Gomez; M Eva Alonso; Jesus Lomas; Jose M de Campos; M Elena Kusak; Jesus Vaquero; Alberto Isla; Manuel Gutierrez; Jose L Sarasa; Juan A Rey Journal: Acta Neuropathol Date: 2004-09-10 Impact factor: 17.088
Authors: Michal Bienkowski; Anna S Berghoff; Christine Marosi; Adelheid Wöhrer; Harald Heinzl; Johannes A Hainfellner; Matthias Preusser Journal: Clin Neuropathol Date: 2015 Sep-Oct Impact factor: 1.368
Authors: Emily J Tonogai; Shan Huang; Rachel C Botham; Matthew R Berry; Stephen K Joslyn; Gregory B Daniel; Zixin Chen; Jianghong Rao; Xiang Zhang; Falguni Basuli; John H Rossmeisl; Gregory J Riggins; Amy K LeBlanc; Timothy M Fan; Paul J Hergenrother Journal: Neuro Oncol Date: 2021-10-01 Impact factor: 13.029